Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: A pilot study

Giorgio Ciprandi, Ignazio Cirillo, Andrea Vizzaccaro, Elisa Civardi, Salvatore Barberi, Michela Allen, Gian Luigi Marseglia

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Background: Nasal obstruction is the main symptom in patients with perennial allergic rhinitis. Some new antihistamines have been demonstrated to be capable of improving this symptom. Objective: The aim of this pilot study was to evaluate nasal symptoms, nasal airflow, eosinophils, and IL-4 in patients with perennial allergic rhinitis, before and after treatment with two new antihistamines: desloratadine and levocetirizine. Methods: Thirty patients with perennial allergic rhinitis were evaluated, 26 males and 4 females (mean age 26 ± 7.1 years). All of them received either desloratadine (5 mg/daily) or levocetirizine (5 mg/daily) or placebo for 4 weeks. The study was double-blind, parallel-group, placebo-controlled, and randomized. Total symptom score (including: rhinorrhea, nasal itching, sneezing, and nasal obstruction) was assessed before and after treatment. Rhinomanometry and decongestion test, nasal lavage, and nasal scraping were performed in all subjects before and after treatment. Eosinophils were counted by conventional staining; IL-4 was measured by immunoassay of fluids recovered from nasal lavage. Results: Desloratadine and levocetirizine treatment induced significant symptom relief and significant reduction of IL-4. Both antihistamines significantly affected all parameters in comparison with placebo. Conclusions: This pilot study demonstrates the effectiveness of antihistaminic treatment in: i) relieving nasal symptoms, including obstruction, ii) improving nasal airflow, iii) exerting decongestant activity, iv) reducing eosinophil infiltration, and v) diminishing IL-4 levels.

Original languageEnglish
Pages (from-to)1800-1808
Number of pages9
JournalInternational Immunopharmacology
Volume5
Issue number13-14
DOIs
Publication statusPublished - Dec 2005

Fingerprint

Rhinitis, Allergic, Perennial
Nose
Inflammation
Interleukin-4
Histamine Antagonists
Eosinophils
Nasal Obstruction
Placebos
Nasal Lavage Fluid
Nasal Lavage
Rhinomanometry
Nasal Decongestants
Sneezing
Therapeutics
Pruritus
Immunoassay
Double-Blind Method
levocetirizine
desloratadine
Staining and Labeling

Keywords

  • Allergic inflammation
  • Decongestion test
  • Desloratadine
  • Levocetirizine
  • Nasal airflow
  • Nasal obstruction
  • Perennial allergic rhinitis
  • Rhinomanometry

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis : A pilot study. / Ciprandi, Giorgio; Cirillo, Ignazio; Vizzaccaro, Andrea; Civardi, Elisa; Barberi, Salvatore; Allen, Michela; Marseglia, Gian Luigi.

In: International Immunopharmacology, Vol. 5, No. 13-14, 12.2005, p. 1800-1808.

Research output: Contribution to journalArticle

@article{e9792dde137b4f9a840ef1b5a394d65e,
title = "Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: A pilot study",
abstract = "Background: Nasal obstruction is the main symptom in patients with perennial allergic rhinitis. Some new antihistamines have been demonstrated to be capable of improving this symptom. Objective: The aim of this pilot study was to evaluate nasal symptoms, nasal airflow, eosinophils, and IL-4 in patients with perennial allergic rhinitis, before and after treatment with two new antihistamines: desloratadine and levocetirizine. Methods: Thirty patients with perennial allergic rhinitis were evaluated, 26 males and 4 females (mean age 26 ± 7.1 years). All of them received either desloratadine (5 mg/daily) or levocetirizine (5 mg/daily) or placebo for 4 weeks. The study was double-blind, parallel-group, placebo-controlled, and randomized. Total symptom score (including: rhinorrhea, nasal itching, sneezing, and nasal obstruction) was assessed before and after treatment. Rhinomanometry and decongestion test, nasal lavage, and nasal scraping were performed in all subjects before and after treatment. Eosinophils were counted by conventional staining; IL-4 was measured by immunoassay of fluids recovered from nasal lavage. Results: Desloratadine and levocetirizine treatment induced significant symptom relief and significant reduction of IL-4. Both antihistamines significantly affected all parameters in comparison with placebo. Conclusions: This pilot study demonstrates the effectiveness of antihistaminic treatment in: i) relieving nasal symptoms, including obstruction, ii) improving nasal airflow, iii) exerting decongestant activity, iv) reducing eosinophil infiltration, and v) diminishing IL-4 levels.",
keywords = "Allergic inflammation, Decongestion test, Desloratadine, Levocetirizine, Nasal airflow, Nasal obstruction, Perennial allergic rhinitis, Rhinomanometry",
author = "Giorgio Ciprandi and Ignazio Cirillo and Andrea Vizzaccaro and Elisa Civardi and Salvatore Barberi and Michela Allen and Marseglia, {Gian Luigi}",
year = "2005",
month = "12",
doi = "10.1016/j.intimp.2005.05.008",
language = "English",
volume = "5",
pages = "1800--1808",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "13-14",

}

TY - JOUR

T1 - Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis

T2 - A pilot study

AU - Ciprandi, Giorgio

AU - Cirillo, Ignazio

AU - Vizzaccaro, Andrea

AU - Civardi, Elisa

AU - Barberi, Salvatore

AU - Allen, Michela

AU - Marseglia, Gian Luigi

PY - 2005/12

Y1 - 2005/12

N2 - Background: Nasal obstruction is the main symptom in patients with perennial allergic rhinitis. Some new antihistamines have been demonstrated to be capable of improving this symptom. Objective: The aim of this pilot study was to evaluate nasal symptoms, nasal airflow, eosinophils, and IL-4 in patients with perennial allergic rhinitis, before and after treatment with two new antihistamines: desloratadine and levocetirizine. Methods: Thirty patients with perennial allergic rhinitis were evaluated, 26 males and 4 females (mean age 26 ± 7.1 years). All of them received either desloratadine (5 mg/daily) or levocetirizine (5 mg/daily) or placebo for 4 weeks. The study was double-blind, parallel-group, placebo-controlled, and randomized. Total symptom score (including: rhinorrhea, nasal itching, sneezing, and nasal obstruction) was assessed before and after treatment. Rhinomanometry and decongestion test, nasal lavage, and nasal scraping were performed in all subjects before and after treatment. Eosinophils were counted by conventional staining; IL-4 was measured by immunoassay of fluids recovered from nasal lavage. Results: Desloratadine and levocetirizine treatment induced significant symptom relief and significant reduction of IL-4. Both antihistamines significantly affected all parameters in comparison with placebo. Conclusions: This pilot study demonstrates the effectiveness of antihistaminic treatment in: i) relieving nasal symptoms, including obstruction, ii) improving nasal airflow, iii) exerting decongestant activity, iv) reducing eosinophil infiltration, and v) diminishing IL-4 levels.

AB - Background: Nasal obstruction is the main symptom in patients with perennial allergic rhinitis. Some new antihistamines have been demonstrated to be capable of improving this symptom. Objective: The aim of this pilot study was to evaluate nasal symptoms, nasal airflow, eosinophils, and IL-4 in patients with perennial allergic rhinitis, before and after treatment with two new antihistamines: desloratadine and levocetirizine. Methods: Thirty patients with perennial allergic rhinitis were evaluated, 26 males and 4 females (mean age 26 ± 7.1 years). All of them received either desloratadine (5 mg/daily) or levocetirizine (5 mg/daily) or placebo for 4 weeks. The study was double-blind, parallel-group, placebo-controlled, and randomized. Total symptom score (including: rhinorrhea, nasal itching, sneezing, and nasal obstruction) was assessed before and after treatment. Rhinomanometry and decongestion test, nasal lavage, and nasal scraping were performed in all subjects before and after treatment. Eosinophils were counted by conventional staining; IL-4 was measured by immunoassay of fluids recovered from nasal lavage. Results: Desloratadine and levocetirizine treatment induced significant symptom relief and significant reduction of IL-4. Both antihistamines significantly affected all parameters in comparison with placebo. Conclusions: This pilot study demonstrates the effectiveness of antihistaminic treatment in: i) relieving nasal symptoms, including obstruction, ii) improving nasal airflow, iii) exerting decongestant activity, iv) reducing eosinophil infiltration, and v) diminishing IL-4 levels.

KW - Allergic inflammation

KW - Decongestion test

KW - Desloratadine

KW - Levocetirizine

KW - Nasal airflow

KW - Nasal obstruction

KW - Perennial allergic rhinitis

KW - Rhinomanometry

UR - http://www.scopus.com/inward/record.url?scp=27744491100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744491100&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2005.05.008

DO - 10.1016/j.intimp.2005.05.008

M3 - Article

C2 - 16275616

AN - SCOPUS:27744491100

VL - 5

SP - 1800

EP - 1808

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 13-14

ER -